Please, Signup (Login) to subscribe or trade (demo)
Biogen Inc. stock price, BIIB
Biogen Inc. stock chart:
Biogen Inc. close price: 254.84
Stock price forecast:
UP TO +2.78%
Total forecasts: 84
Reached: 36 (42.86%)
Total Win: 246.77 (90.85%)
Showing 1-10 of 512 items.
|Date of Forecast||Stock Price||Target Price||Forecast Reached Date|
Biogen Inc. latest news:
Biogen's stock jumps after UBS boosts rating, price target
Shares of Biogen Inc. ran up 3.9% in afternoon trade Monday, to turn positive on the year, after UBS backed away from its bearish rating on the belief valuation may have bottomed. Analyst Carter Gould raised his rating to neutral from sell and raised his stock price target to $270, which is 3.2% above current levels, from $262. The stock is now up 0.2% year to date, while the iShares Nasdaq Biotechnology ETF has run up 13.1% and the S&P 500 has gained 9.4%. Gould said concerns over competition to Biogen's Spinraza for spinal muscular atrophy from gene therapy is already priced into the stock price, and sentiment has neared a bottom after the departure of its chief financial officer last week. Gould said he is also "more constructive" on Biogen's aducanumab Alzheimer's treatment. Although he believes intensifying competition will continue to weigh on the company's multiple sclerosis franchise, but he sees that "increasingly balanced by a growing focus on aducanumab."Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Biogen and Anadarko slump while H&R Block and Southern rise
Biogen and Anadarko Petroleum fall while H&R Block and Southern trade higher
Alexion names Biogen's Paul Clancy as CFO
Alexion Pharmaceuticals Inc(ALXN) on Tuesday named Biogen Inc's Chief Financial Officer Paul Clancy as its finance head, effective July 31. Clancy will succeed Dave Anderson, who will remain with Alexion until August end, the company said. Alexion shares were up 3.7 percent in extended trading while Biogen shares were down 1.9 percent.
Alexion hires Biogen executive to serve as its CFO
Shares of Alexion Pharmaceuticals Inc. rose more than 2% late Tuesday after the company announced the hiring of the former Biogen Inc. chief financial officer as its CFO. Paul J. Clancy will join Alexion on July 31 after having served as Biogen's CFO for the past 10 years, the company said in a statement. Clancy succeeds Dave Anderson, who will continue to serve as CFO until July 31. "To ensure a smooth transition, (Anderson) will then become a Senior Advisor to the Chief Executive Officer and will remain with Alexion until the end of August," the company said in a statement. Shares of Biogen fell 1.8%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
What's Worrying Me About Biogen
Biogen could struggle to maintain its market-leading position in multiple sclerosis over the next two years.
Biogen stock rises after first-quarter earnings, profit beat
Biogen Inc. shares rose as much as 4.8% in premarket trade Tuesday after the company reported a first-quarter earnings and profit beat. Earnings for the latest quarter declined to $747.6 million, or $3.46 per share, from $970.9 million, or $4.43 per share, in the year-earlier period. The latest results include the $263 million cost of a settlement and license agreement with Forward Pharma , Biogen said. Adjusted earnings-per-share were $5.20, compared with the FactSet consensus of $4.97. Revenue rose to $2.81 billion from $2.73 billion, compared with the FactSet consensus of $2.73 billion. Revenue from Biogen's key multiple sclerosis drug, Tecfidera, rose to $958.2 million from $945.2 million, below the FactSet consensus of $977.5 million. Biogen shares have surged 10.0% over the last three months, compared with a 3.3% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Biogen wins Tecfidera U.S. patent dispute with Forward Pharma
A U.S. patent board on Friday ruled against Danish drugmaker Forward Pharma A/S (FWP), finding Biogen's patents on its blockbuster multiple sclerosis drug Tecfidera to be valid. The ruling by the U.S. Patent Trial and Appeal Board frees Bigoen Inc from future royalty payments to Forward and sent the Danish firm's shares down nearly 20 percent.
Biogen stock rises, Forward Pharma halted down 20% after patent ruling
Shares of Biogen Inc. (BIIB) rose Friday, while Forward Pharma A/S (FWP) shares were halted after falling almost 20%, after Biogen was reported to have won a patent ruling. Patent Office ruled in favor of Biogen in a patent interference proceeding related to its multiple sclerosis drug Tecfidera, according to Evercore ISI analyst Umer Raffat. Biogen paid Forward Pharma (FWP) $1.25 billion in February related to the patent that covers ways of treating MS patients.
BioLife Solutions, Inc.BLFS
BioMarin Pharmaceutical Inc.BMRN
BiondVax Pharmaceuticals Ltd.BVXV
BiondVax Pharmaceuticals Ltd.BVXVW
Bio-Path Holdings, Inc.BPTH
BioShares Biotechnology Clinical Trials FundBBC
BioShares Biotechnology Products FundBBP